Literature DB >> 20340127

Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer.

Kazumori Kawakami1, Soichiro Yamamura, Hiroshi Hirata, Koji Ueno, Sharanjot Saini, Shahana Majid, Yuichiro Tanaka, Ken Kawamoto, Hideki Enokida, Masayuki Nakagawa, Rajvir Dahiya.   

Abstract

Secreted frizzled-related protein-5 (sFRP-5) has been identified as 1 of the secreted antagonists that bind Wnt protein. However, the functional significance of sFRP-5 in renal cell cancer (RCC) has not been reported. We hypothesized that sFRP-5 may be epigenetically downregulated through DNA methylation and histone modification and function as a tumor suppressor gene in RCC. Using tissue microarray and real-time RT-PCR, we found that sFRP-5 was significantly downregulated in kidney cancer tissues and cell lines, respectively. DNA bisulfite sequencing of the sFRP-5 promoter region in RCC cell lines showed it to be densely methylated, whereas there was few promoter methylation in normal kidney. The sFRP-5 expression was restored and the acetylation of H3 and H4 histones associated with the sFRP-5 promoter region were significantly increased after treatment with demethylation agent (5-Aza-dc) and histone deacetylase inhibitor (TSA). When RCC cells were transfected with the sFRP-5 gene, significant inhibition of anchorage independent colony formation and cell invasion were observed compared to controls. The sFRP-5 transfection also significantly induced apoptosis in RCC cells. In conclusion, this is the first report documenting that the sFRP-5 is downregulated by promoter methylation and histone acetylation and functions as a tumor suppressor gene by inducing apoptosis in RCC cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20340127      PMCID: PMC3940353          DOI: 10.1002/ijc.25357

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

1.  Retinoic acid receptor beta2 is epigenetically silenced either by DNA methylation or repressive histone modifications at the promoter in cervical cancer cells.

Authors:  Zhongming Zhang; Keiichiro Joh; Hitomi Yatsuki; Wei Zhao; Hidenobu Soejima; Ken Higashimoto; Mitsuyo Noguchi; Masatoshi Yokoyama; Tsuyoshi Iwasaka; Tsunehiro Mukai
Journal:  Cancer Lett       Date:  2006-06-27       Impact factor: 8.679

Review 2.  Dual targeting of epigenetic therapy in cancer.

Authors:  Debby M E I Hellebrekers; Arjan W Griffioen; Manon van Engeland
Journal:  Biochim Biophys Acta       Date:  2006-07-21

3.  Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.

Authors:  Shinji Urakami; Hiroaki Shiina; Hideki Enokida; Hiroshi Hirata; Ken Kawamoto; Toshifumi Kawakami; Nobuyuki Kikuno; Yuichiro Tanaka; Shahana Majid; Masayuki Nakagawa; Mikio Igawa; Rajvir Dahiya
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

4.  Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.

Authors:  Shinji Urakami; Hiroaki Shiina; Hideki Enokida; Toshifumi Kawakami; Ken Kawamoto; Hiroshi Hirata; Yuichiro Tanaka; Nobuyuki Kikuno; Masayuki Nakagawa; Mikio Igawa; Rajvir Dahiya
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

5.  Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.

Authors:  E Dahl; F Wiesmann; M Woenckhaus; R Stoehr; P J Wild; J Veeck; R Knüchel; E Klopocki; G Sauter; R Simon; W F Wieland; B Walter; S Denzinger; A Hartmann; C G Hammerschmied
Journal:  Oncogene       Date:  2007-03-12       Impact factor: 9.867

6.  Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription.

Authors:  J C Tapia; V A Torres; D A Rodriguez; L Leyton; A F G Quest
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-27       Impact factor: 11.205

7.  Methylation analysis of SFRP genes family in cervical adenocarcinoma.

Authors:  Ya-Wen Lin; Ming-Tzeung Chung; Hung-Cheng Lai; Ming De Yan; Yu-Leung Shih; Cheng-Chang Chang; Mu-Hsien Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-10       Impact factor: 4.553

Review 8.  Roles of secreted frizzled-related proteins in cancer.

Authors:  Yihui Shi; Biao He; Liang You; David M Jablons
Journal:  Acta Pharmacol Sin       Date:  2007-09       Impact factor: 6.150

9.  Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma.

Authors:  Michelle L Gumz; Hongzhi Zou; Pamela A Kreinest; April C Childs; Leandra S Belmonte; Shauna N LeGrand; Kevin J Wu; Bruce A Luxon; Mala Sinha; Alexander S Parker; L-Z Sun; David A Ahlquist; Christopher G Wood; John A Copland
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

10.  Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer.

Authors:  Chenghai Zhao; Xianmin Bu; Ning Zhang; Wei Wang
Journal:  BMC Cancer       Date:  2009-07-09       Impact factor: 4.430

View more
  25 in total

1.  Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Authors:  Simon J Cooper; Christina A von Roemeling; Kylie H Kang; Laura A Marlow; Stefan K Grebe; Michael E Menefee; Han W Tun; Gerardo Colon-Otero; Edith A Perez; John A Copland
Journal:  Mol Cancer Ther       Date:  2012-07-23       Impact factor: 6.261

2.  Low expression of RBMS3 and SFRP1 are associated with poor prognosis in patients with gastric cancer.

Authors:  Tao Zhang; Youliang Wu; Zheng Fang; Qiang Yan; Shangxin Zhang; Ruochuan Sun; Junaid Khaliq; Yongxiang Li
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

3.  Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.

Authors:  Hashem O Alsaab; Samaresh Sau; Rami M Alzhrani; Vino T Cheriyan; Lisa A Polin; Ulka Vaishampayan; Arun K Rishi; Arun K Iyer
Journal:  Biomaterials       Date:  2018-08-30       Impact factor: 12.479

4.  Silencing of Wnt5a during colon cancer metastasis involves histone modifications.

Authors:  Qian Li; Hong Chen
Journal:  Epigenetics       Date:  2012-06-01       Impact factor: 4.528

Review 5.  The complex roles of Wnt antagonists in RCC.

Authors:  Sharanjot Saini; Shahana Majid; Rajvir Dahiya
Journal:  Nat Rev Urol       Date:  2011-10-25       Impact factor: 14.432

6.  Methylation of SFRP5 is related to multidrug resistance in leukemia cells.

Authors:  H Wang; X Wang; R Hu; W Yang; A Liao; C Zhao; J Zhang; Z Liu
Journal:  Cancer Gene Ther       Date:  2014-01-17       Impact factor: 5.987

Review 7.  Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.

Authors:  Swathi Ramakrishnan; Roberto Pili
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

8.  Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer.

Authors:  Antoinette S Perry; Gillian O'Hurley; Omer A Raheem; Kevin Brennan; Simon Wong; Anthony O'Grady; Anne-Marie Kennedy; Laure Marignol; Therese M Murphy; Linda Sullivan; Ciara Barrett; Barbara Loftus; John Thornhill; Stephen M Hewitt; Mark Lawler; Elaine Kay; Thomas Lynch; Donal Hollywood
Journal:  Int J Cancer       Date:  2012-09-28       Impact factor: 7.396

9.  Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma.

Authors:  Youtu Wu; Jiwei Bai; Zhenye Li; Fei Wang; Lei Cao; Chunhui Liu; Shengyuan Yu; Guoqiang Yu; Yazhuo Zhang
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

10.  WNT10A plays an oncogenic role in renal cell carcinoma by activating WNT/β-catenin pathway.

Authors:  Ren-Jun Hsu; Jar-Yi Ho; Tai-Lung Cha; Dah-Shyong Yu; Chieh-Lin Wu; Wei-Ping Huang; Pauling Chu; Ying-Hsin Chen; Jiann-Torng Chen; Cheng-Ping Yu
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.